Cefepime vs. Piperacillin-Tazobactam for Pseudomonas Pneumonia
The 2026 IDSA AMR Guidance: What Changed, Why It Changed, and What You Do Monday Morning
The Contrast Nephropathy That Wasn't
Staphylococcus aureus Bacteremia in 2026: A New Guideline, a Landmark Trial, and What It Means at the Bedside
Does glucosamine accelerate Alzheimer’s? A big claim, a small denominator
The First Oral Carbapenem Arrives - Tebipenem pivoxil (Utebzi): what it is, where it earns its place, and where it absolutely does not
Baxdrostat vs. Spironolactone: A New Mechanism Meets an Old Bargain - THE $5-BILLION QUESTION
IV Iron in Oncology: Time to Rethink Your Default
When the New β-Lactam/β-Lactamase Inhibitors Aren’t Enough
Asundexian for Secondary Stroke Prevention OCEANIC-STROKE — A Three-Lens Critical Appraisal
OCEANIC-STROKE met its primary endpoint with a 26% relative reduction in ischemic stroke and no excess major bleeding — but the prespecified hierarchy broke at the 90-day endpoint. A statistician, a neurologist, and a researcher walk into a journal club. Here's what they each see.
